Vera Therapeutics' TRUTAKNA (Atacicept-Vymj) Cuts Composite Kidney Progression Risk 76% Over 104 Weeks in Phase 3 ORIGIN 3 Final Analysis in IgA Nephropathy
Vera Therapeutics reported on Tuesday, September 15, 2026 final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in 428 adults with primary IgA nephropathy at risk of progression. At 52 weeks, mean eGFR changed by -0.1 mL/min/1.73m² on TRUTAKNA versus -5.7 on placebo, and the annualized eGFR slope through 104 weeks was -0.6 versus -5.6 mL/min/1.73m² per year. TRUTAKNA cut the risk of composite kidney disease progression by 76% (hazard ratio 0.24; 11 versus 38 events), with no dialysis, transplant, or death events versus 8 on placebo, and proteinuria, galactose-deficient IgA1, and hematuria also fell significantly. Safety was generally comparable to placebo. Vera plans to submit a supplemental BLA for full approval in the fourth quarter of 2026 and reported more than 350 patient start forms in the first ten weeks of launch.